Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations.

Affiliation

University of Colorado School of Medicine, Denver, CO, USA. [Email]

Abstract

Androgen deprivation therapy (ADT) is foundational in the management of advanced prostate cancer (PCa) and has benefitted from a recent explosion in scientific advances. These include approval of new therapies that suppress testosterone (T) levels or inactivate its function, improvements in diagnostic and assay technologies, identification of lower therapeutic targets for T, discovery of the relevance of germline genetic mutations and identification of the benefits of sequential and combination therapies.